Merck stock in focus as MRK lifts $70 billion mid-2030s target and points past Keytruda
New York, Jan 12, 2026, 21:31 EST — The market has closed. Merck & Co boosted its long-term revenue forecast for several new products and pipeline candidates, projecting $70 billion from these “new growth drivers” by the mid-2030s. The company raised its cardiometabolic and respiratory sales outlook to around $20 billion, up from $15 billion, while its infectious-disease forecast jumped…